Avecho Biotechnology Limited (AVE.AX)

0.0040 0.0000 (0.00%) At close: 04:10PM AEST

Avecho Biotechnology Limited

2A Westall Road
Unit A8
Clayton, VIC 3168
Australia
61 3 9002 5000
https://avecho.com.au

Sector(s): Healthcare
Industry: Biotechnology
Full-time employees: 

Key executives

Name	Title	Pay	Exercised	Year born
Dr. Paul Gavin BSc (Hons), Ph.D.	Chief Executive Officer	259.65k	N/A	N/A
Dr. Roksan Libinaki Ph.D.	Chief Operating Officer	226.63k	N/A	N/A
Ms. Melanie Jaye Leydin B.Bus, C.A.	Company Secretary & CFO	N/A	N/A	1973

Amounts are as of 31 December 2023, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in AUD.

Description

Avecho Biotechnology Limited, a biotechnology company, engages in the development and commercialization of human and animal health related products using its proprietary drug delivery system and Tocopherol Phosphate Mixture in Australia. The company operates through Production and Human Health segments. It also produces and sells TPM and Vital ET products for use in drug delivery and cosmetic formulations. In addition, the company's human health portfolio covers delivery of pharmaceutical products through gels, injectables, and patches. Further, it develops feed additive products to enhance feed efficiency and the health of livestock animals. The company has a collaboration with Lambert Initiative at the University of Sydney for treatment of osteoarthritis. The company was incorporated in 1992 and is based in Clayton, Australia.

Corporate governance

Avecho Biotechnology Limited’s ISS governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.